Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease

NCT02674308 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02674308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02674308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
March 24, 2015
Completion date
July 30, 2021
Enrollment
5,302 (actual)
Sites
287

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis and crohn's disease